Jack W. Plunkett

Plunkett's Biotech & Genetics Industry Almanac 2011: Biotech & Genetics Industry Market Research, Statistics, Trends & Leading Companies Jack W. Plunkett 1 Pap / Psc edition

PLUNKETT'S BIOTECH & GENETICS INDUSTRY ALMANAC 2011

Key Features:
-Industry trends analysis, market data and competitive intelligence
-Market forecasts and Industry Statistics
-Industry Associations and Professional Societies List
-In-Depth Profiles of hundreds of leading companies
-Industry Glossary
-Buyer may register for access to search and export data at Plunkett Research Online

Pages: 546
Statistical Tables Provided: 21
Companies Profiled: 364
Geographic Focus: Global

A complete market research report, including forecasts and market estimates, technologies analysis and developments at innovative firms.
You will gain vital insights that can help you shape your own strategy for business development, product development and investments.
-How is the industry evolving?
-How is the industry being shaped by new technologies?
-How is demand growing in emerging markets and mature economies?
-What is the size of the market now and in the future?
-What are the financial results of the leading companies?
-What are the names and titles of top executives?

Contents, Statistics, Forecasts and Analysis Include:
Major Trends Affecting the Biotech & Genetics Industry
1) The State of the Biotechnology Industry Today
2) A Short History of Biotechnology
3) Ethanol Production Soared, But a Market Glut May Slow Expansion
4) Major Drug Companies Bet on Partnerships With Smaller Biotech Research Firms
5) From India to Singapore to Australia, Nations Compete Fiercely in Biotech Development
6) Medical Trials Conducted Abroad Spark Concerns
7) Gene Therapies and Patients' Genetic Profiles Promise a Personalized Approach to Medicine
8) Breakthrough Drugs for Cancer Treatment; Many More Will Follow
9) Few New Blockbusters: Major Drug Patents Expire While Generic Sales Growth Continues
10) Biotech and Orphan Drugs Pick Up the Slack as Blockbuster Mainstream Drugs Age
11) Biogenerics (Follow-on Biologics) are in Limbo in the U. S.
12) Breakthrough Drug Delivery Systems Evolve
13) Stem Cells: Multiple Sources Stem from New Technologies
14) U. S. Government Reverses Ban on Funding for New Stem Cell Research
15) Stem Cells: Therapeutic Cloning Techniques Advance
16) Stem Cells: A New Era of Regenerative Medicine Takes Shape
17) Nanotechnology Converges with Biotech
18) Agricultural Biotechnology Scores Breakthroughs but Causes Controversy/Selective Breeding Offers a Compromise
19) Focus on Vaccines
20) Ethical Issues Abound

Biotech & Genetics Industry Statistics
1) U. S. FDA New Drug and Biologic Approvals, 2009
2) U. S. Pharmaceutical R&D Spending Versus the Number of New Molecular Entity (NME) Approvals: 1993-2009
3) Federal R&D & R&D Plant Funding for General Science & Basic Research, U. S.: Fiscal Years 2008-2010
4) National Health Expenditure Amounts by Type of Expenditure, U. S.: Selected Calendar Years, 2004-2019
5) U. S. Exports & Imports of Pharmaceutical Products: 2005-1st Quarter 2010
6) U. S. Prescription Drug Expenditures, Aggregate & Per Capita Amounts, Percent Distribution: Selected Calendar Years, 2004-2019
7) U. S. Prescription Drug Expenditures: 1965-2019
8) Total U. S. Biotechnology Patents Granted per Year by Patent Class: 1977-2009
9) Research Funding for Biological Sciences, U. S. National Science Foundation: Fiscal Year 2009-2011
10) Sales By Geographic Area, PhRMA Member Companies: 2008
11) Domestic U. S. Biopharmaceutical R&D Breakdown, PhRMA Member Companies: 2008
12) R&D by Global Geographic Area, PhRMA Member Companies: 2008
13) Domestic Biopharmaceutical R&D Scientific, Professional & Technical Personnel by Function, PhRMA Member Companies: 2008
14) Domestic U. S. Biopharmaceutical R&D & R&D Abroad, PhRMA Member Companies: 1970-2009